Birchview Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-80,000
Closed -$182K 63
2024
Q2
$182K Hold
80,000
0.17% 50
2024
Q1
$346K Hold
80,000
0.28% 42
2023
Q4
$244K Sell
80,000
-40,000
-33% -$75.2K 0.19% 46
2023
Q3
$173K Buy
120,000
+80,000
+200% +$155K 0.15% 47
2023
Q2
$99.6K Hold
40,000
0.07% 52
2023
Q1
$107K Hold
40,000
0.08% 51
2022
Q4
$217K Hold
40,000
0.15% 49
2022
Q3
$500K Hold
40,000
0.35% 38
2022
Q2
$198K Hold
40,000
0.14% 52
2022
Q1
$304K Hold
40,000
0.22% 51
2021
Q4
$408K Hold
40,000
0.26% 48
2021
Q3
$537K Hold
40,000
0.37% 38
2021
Q2
$878K Hold
40,000
0.53% 36
2021
Q1
$962K Hold
40,000
0.57% 31
2020
Q4
$720K Hold
40,000
0.41% 34
2020
Q3
$462K Hold
40,000
0.31% 34
2020
Q2
$970K Hold
40,000
0.59% 23
2020
Q1
$441K Hold
40,000
0.39% 31
2019
Q4
$1.06M Hold
40,000
0.77% 20
2019
Q3
$911K Hold
40,000
0.61% 15
2019
Q2
$1.23M Buy
40,000
+25,000
+167% +$526K 0.75% 12
2019
Q1
$249K Hold
15,000
0.16% 43
2018
Q4
$287K Hold
15,000
0.27% 39
2018
Q3
$784K Sell
15,000
-7,000
-32% -$382K 0.51% 21
2018
Q2
$956K Hold
22,000
0.65% 17
2018
Q1
$815K Buy
+22,000
New +$587K 0.54% 16

Birchview Capital's GTHX Position: Q3 2024 in Review

Birchview Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 80,000 shares — an estimated $182K sold.

Birchview Capital first reported a position in GTHX in Q1 2018 and held it in 26 quarters. The position peaked at $1.23M in Q2 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Birchview Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Birchview Capital sold 80,000 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $182K.
  • Birchview Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 26 quarters.
  • Birchview Capital's G1 Therapeutics, Inc. Common Stock position peaked at $1.23M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Birchview Capital's 13F filing for Q3 2024, filed 14 Nov 2024.